Therapeutic peptides: how they mimic hormones your body already makes
What a therapeutic peptide is, how it relates to the insulin and GLP-1 your body already makes, and why nearly all of them are modified before prescription.
A therapeutic peptide is a short, ordered chain of amino acids, usually between 500 and 5000 daltons, that binds to receptors on the cell surface and triggers a specific physiological response. Almost none of them were designed from scratch. They started as copies of hormones the human body already produces, and their sequences were then modified so they would last longer in the body.
What a peptide actually is
A peptide is a sequence of amino acids joined by amide bonds, which is something it shares with proteins. What differs is size. Therapeutic peptides sit between 500 and 5000 daltons, below proteins and above classic small molecules.
That middle position gives them distinct behaviour. They act as hormones, growth factors, neurotransmitters, ion channel ligands, or anti-infective agents, and they do so by binding to cell-surface receptors with high affinity and high specificity. That affinity and specificity are also why peptide treatment depends on a prescription and prior assessment; you can see how the peptide therapy protocol works at Nectalis.
Your body already makes peptide hormones
This drug class starts in biology, not in a design lab. The first therapeutic peptides were obtained from natural human hormones whose physiological behaviour was already well studied.
| Endogenous peptide | Amino acids | Function |
|---|---|---|
| GnRH (gonadotropin-releasing hormone) | 10 | Produced by neurons in the hypothalamus; regulates the reproductive axis |
| GLP-1 (glucagon-like peptide 1) | 37 | Regulates insulin production and secretion |
| Insulin | 51 | Regulates blood glucose |
Insulin deserves its own line because it came first. It was isolated in 1921, and by 1923 it was the first commercial peptide drug. More than 80 peptide drugs are approved worldwide today.
When the natural peptide was not enough, the strategy stopped being extraction and became modification.
What peptides offer compared with other molecules
Compared with biologics
Biologics include therapeutic proteins and antibodies. Peptides share their mode of action, since they also act on surface receptors. The difference is in two costs: peptides show lower immunogenicity, and they are cheaper to produce.
Compared with small molecules
Here the difference is geometry. Small molecules have well-known advantages: oral administration, good membrane penetration, and low cost. Their size is also their limit. A protein-to-protein interaction occupies a contact area of 1500 to 3000 Ų, while a small molecule covers only 300 to 1000 Ų. That is why it struggles to inhibit such interactions.
Specificity is the other issue. Sorafenib and sunitinib, for instance, inhibit the tyrosine kinase domain of VEGF receptors and produce an anti-angiogenic effect, but they also act on other receptors, which translates into cytotoxicity. Peptides, with a larger contact surface and a more flexible chain, have more room to be selective.
Their two built-in problems
Every therapeutic peptide starts with two intrinsic limitations.
They do not cross cell membranes well. Permeability depends on length and amino acid composition, but in general they cannot enter the cell, so they only reach extracellular targets. In 2018, Lau and Dunn reported that more than 90% of peptides in active clinical development targeted extracellular targets, among them G protein-coupled receptors, the GnRH receptor, and the GLP-1 receptor.
They degrade quickly. The chain is held together by amide bonds, and without the protection that a protein's secondary and tertiary structures provide, those bonds hydrolyse easily. The result is a short half-life and rapid elimination.
These two limitations explain why a natural peptide rarely works as a drug on its own, and why nearly all of those prescribed today are modified versions. How far a peptide's capability actually reaches is set out in what a therapeutic peptide can and cannot do.
How the duration problem was solved
Chemically modifying the sequence is the most common answer. Three cases show how it works.
GLP-1: a hormone the body destroys within minutes
This is a 37-amino-acid peptide with a very short half-life, because the enzyme DPP-4 degrades and inactivates it quickly. Modifying its sequence preserved potency while adding stability, and that work produced the GLP-1 analogues in use today. The first was approved in 2005, followed by others in 2009, 2013, 2014, and 2017. Longer-acting versions are also administered less frequently, with better adherence. Where that hormone is produced and exactly what it does is covered in what GLP-1 is and how it works.
GnRH: the same molecule, two opposite effects
A 10-amino-acid peptide produced by neurons in the hypothalamus. Modifying its sequence produced drugs with opposite effects from the same base molecule: leuprolide acts as an agonist, activating the receptor, while degarelix acts as an antagonist, competing for it. What decides the effect is not the starting molecule but which part of the chain is changed.
Other hormones and other routes
The same principle produced octreotide, a somatostatin mimic; desmopressin, a mimic of 8-arginine vasopressin; and carbetocin, an oxytocin homologue. Beyond chemical modification, other routes exist for extending half-life, such as PEGylation, which attaches polyethylene glycol chains to the molecule.
What this means when a treatment is involved
A peptide mimicking a natural hormone does not make it harmless. It means the molecule acts on receptors the body uses for real functions, so it has effects and it has adverse effects.
For GLP-1 analogues, the reviewed literature describes the most frequent adverse reactions as gastrointestinal: mainly nausea, vomiting, and diarrhoea, along with injection-site reactions. That is why they are prescription medicines requiring clinical follow-up.
On compounded formulations, precision matters: the base active ingredient holds FDA approval in its brand-name reference medicines. Personalised compounded formulations are prepared and dispensed by state-licensed 503A pharmacies under strict individualised medical prescription following a clinical consultation. A compounded medicine is not an FDA-approved equivalent of a brand-name product.
Frequently asked questions
Is a peptide the same as a protein?
No. Both are made of amino acids joined by amide bonds, but therapeutic peptides are much shorter, between 500 and 5000 daltons, whereas proteins have longer chains and stable secondary and tertiary structures, which is what makes them more resistant to degradation.
Why are many peptides injected rather than taken orally?
Because they do not cross the digestive tract membrane well, and because enzymes break them down before they reach the bloodstream. Injection avoids both obstacles.
Is a modified peptide worse than a natural one?
No. The modifications exist to correct the two built-in problems: poor stability and rapid degradation. A natural peptide cleared within minutes may never produce the intended effect.
Are therapeutic peptides safe?
They are prescription medicines with documented adverse effects. Whether a specific treatment is appropriate for a given person is a judgement for a licensed professional, who reviews history, concurrent medication, and contraindications. Individual results vary according to each person's biological response.
If you want to know whether a peptide-based treatment is right for you
Not everyone is a candidate, and that is not a determination an article can make. At Nectalis, a licensed professional reviews your history and your situation before any treatment is considered, and follow-up continues after the initial consultation.
Start your clinical evaluation →
Sources
- Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C. Therapeutic peptides: current applications and future directions. *Signal Transduction and Targeted Therapy.* 2022;7(1):48. doi:10.1038/s41392-022-00904-4. Licence CC BY 4.0.
- Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. *Bioorganic & Medicinal Chemistry.* 2018;26(10):2700-2707. doi:10.1016/j.bmc.2017.06.052.
Medical Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Always consult your physician before making any changes to your medication or lifestyle regimen.
Interested in personalized medical protocols?
Explore our compounded GLP-1, 503A Peptides, and hormone optimization options.